FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Stock analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of Cullinan Therapeutics in a note issued to investors on Monday, October 28th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of $0.54 for the year. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.20) per share.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Cullinan Therapeutics in a research report on Wednesday, October 16th. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Cullinan Therapeutics in a report on Wednesday, September 18th. Finally, UBS Group initiated coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $30.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $31.67.

Cullinan Therapeutics Stock Performance

Shares of NASDAQ:CGEM opened at $15.55 on Wednesday. The company’s fifty day moving average is $17.16 and its two-hundred day moving average is $19.15. Cullinan Therapeutics has a 1-year low of $7.64 and a 1-year high of $30.19. The stock has a market capitalization of $901.54 million, a price-to-earnings ratio of -5.08 and a beta of -0.13.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02).

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $18.09, for a total transaction of $144,720.00. Following the completion of the transaction, the insider now directly owns 115,942 shares in the company, valued at approximately $2,097,390.78. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Amalgamated Bank increased its stake in Cullinan Therapeutics by 97.3% during the 3rd quarter. Amalgamated Bank now owns 1,768 shares of the company’s stock valued at $30,000 after buying an additional 872 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in shares of Cullinan Therapeutics by 22.2% in the third quarter. Harbor Capital Advisors Inc. now owns 21,362 shares of the company’s stock valued at $358,000 after acquiring an additional 3,881 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Cullinan Therapeutics by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,151 shares of the company’s stock valued at $187,000 after acquiring an additional 4,380 shares during the period. Assenagon Asset Management S.A. raised its holdings in Cullinan Therapeutics by 18.3% during the third quarter. Assenagon Asset Management S.A. now owns 135,036 shares of the company’s stock worth $2,261,000 after purchasing an additional 20,841 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in Cullinan Therapeutics in the second quarter worth approximately $13,079,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.